Evaluation of the Clinical Drug‐Drug Interaction Potential of Pritelivir on Transporters and CYP450 Enzymes Using a Cocktail Approach
Clinical Pharmacology in Drug Development · 2024-07 · 13 (7) · 755-769
DOI: 10.1002/cpdd.1408 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Clinical Pharmacology in Drug Development, online erschienen am 16.05.2024. Verfasst von Michiel de Vries und 6 weiteren Autor:innen. Beteiligte Einrichtung: Molenpad ClinPharm Support, Weesp, The Netherlands. Hauptthemen laut MEDLINE: Drug Interactions, Cytochrome P-450 Enzyme System, ATP Binding Cassette Transporter, Subfamily G, Member 2. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Pritelivir is a novel viral helicase‐primase inhibitor active against herpes simplex virus. In vitro drug‐drug interaction studies indicated that pritelivir has the potential for clinically relevant interactions on the cytochrome P450 (CYP) enzymes 2C8, 2C9, 3A4, and 2B6, and intestinal uptake transporter organic anion transporting polypeptide (OATP) 2B1 and efflux transporter breast cancer resistance protein (BCRP). This was evaluated in 2 clinical trials. In 1 trial the substrates flurbiprofen (CYP2C9), bupropion (CYP2B6), and midazolam (CYP3A4) were administered simultaneously as part of the Geneva cocktail, while the substrate celiprolol (OAPT2B1) was administered separately. In another trial, the substrates repaglinide (CYP2C8) and rosuvastatin (BCRP) were administered separately. Exposure parameters of the substrates and their metabolites (flurbiprofen and bupropion only) were compared after administration with or without pritelivir under therapeutic concentrations. The results of these trials indicated that pritelivir has no clinically relevant effect on the exposure of substrates for the intestinal uptake transporter OATP2B1 and the CYP enzymes 3A4, 2B6, 2C9, and 2C8, and has a weak inhibitory effect on the intestinal efflux transporter BCRP. In summary, the results suggest that pritelivir has a low drug‐drug interaction potential.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Molenpad ClinPharm Support, Weesp, The Netherlands.
- AiCuris Anti-infective Cures AG, Wuppertal, Germany.
- Present affiliation: BioNTech SE, Mainz, Germany.
Zitieren
APA
de Vries, M., Bonsmann, S., Pausch, J., Sumner, M., Birkmann, A., Zimmermann, H., & Kropeit, D. (2024). Evaluation of the Clinical Drug‐Drug Interaction Potential of Pritelivir on Transporters and CYP450 Enzymes Using a Cocktail Approach. Clinical Pharmacology in Drug Development, 13(7), 755-769. https://doi.org/10.1002/cpdd.1408
Vancouver
de Vries M, Bonsmann S, Pausch J, Sumner M, Birkmann A, Zimmermann H, et al. Evaluation of the Clinical Drug‐Drug Interaction Potential of Pritelivir on Transporters and CYP450 Enzymes Using a Cocktail Approach. Clinical Pharmacology in Drug Development. 2024;13(7):755-769. doi:10.1002/cpdd.1408
BibTeX
@article{deVries2024,
author = {de Vries, Michiel and Bonsmann, Susanne and Pausch, Jörg and Sumner, Melanie and Birkmann, Alexander and Zimmermann, Holger and Kropeit, Dirk},
title = {Evaluation of the Clinical Drug‐Drug Interaction Potential of Pritelivir on Transporters and CYP450 Enzymes Using a Cocktail Approach},
journal = {Clinical Pharmacology in Drug Development},
year = {2024},
volume = {13},
number = {7},
pages = {755--769},
doi = {10.1002/cpdd.1408}
}
EUVIMED